Effects of Acarbose on Polycystic Ovary Syndrome: A Meta-analysis

Abstract

Objective: Whether or not acarbose benefits patients with polycystic ovary syndrome (PCOS) remains controversial. Therefore, we performed a meta-analysis to synthesize the literature regarding the therapeutic effects of acarbose on PCOS.

Methods: A comprehensive literature search was performed using terms, such as polycystic ovary syndrome, ovary polycystic disease, PCOS, hyperandrogenemia, acarbose, alpha-glucosidase inhibitors, and randomized controlled trials (RCTs), in the following bibliographic databases: Medline; Embase; and Cochrane Controlled Trials Register. The identified reference lists were checked manually.

Results: 6 RCTs met the inclusion criteria. Based on the meta-analysis of 3 studies, acarbose was superior to placebo or no treatment in reducing serum levels of testosterone (Std MD=− 3.38, 95% CI:−5.97~−0.78, P=0.01) and acarbose caused a significantly higher incidence of side effects, such as abdominal distention and diarrhea (OR=23.78, 95% CI: 5.67~99.75, P<0.0001). The changes in Ferriman-Gallwey score or body mass index (BMI) were not significant. Based on the meta-analysis of 2 studies, acarbose were superior to placebo or no treatment in reducing triglycerides (TG; WMD=−18.18, 95% CI:−36.30~−0.06, P=0.05) and very low-density lipoprotein (VLDL) cholesterol (WMD=− 6.49, 95% CI:−9.14~−3.84, P<0.00001), and increasing high-density lipoprotein (HDL) cholesterol (WMD=5.14, 95% CI:1.73~8.55, P=0.003). There were no significant differences between acarbose and metformin with respect to improvements in ovulation rate, menstrual patterns, or changes in serum levels of testosterone, adverse events, or BMI. Heterogeneities were detected during the meta-analysis.

Conclusions: This is the first meta-analysis to evaluate the role that acarbose plays in the treatment of PCOS. The currently available data showed that acarbose can reduce testosterone, TG, and VLDL, and increase HDL. Acarbose caused a significantly higher incidence of gastrointestinal disturbance. Given the small RCTs and poor quality of RCTs included, these results are not conclusive. A large-scale, randomized controlled study is needed to ascertain this uncertainty.

Key words

polycystic ovary syndrome (PCOS) - acarbose - meta-analysis

• References

• 1 Gangale MF, Miele L, Lanzone A et al. Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol 2011; 75: 520-527
• 2 Kim JJ, Choi YM, Cho YM et al. Prevalence of elevated glycated hemoglobin in women with polycystic ovary syndrome. Hum Reprod 2012; 27: 1439-1444
• 3 Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853-861
• 4 Nestler JE. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Semin Reprod Endocrinol 1997; 15: 111-122
• 5 Dunaif A, Scott D, Finegood D et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81: 3299-3306
• 6 Ehrmann DA, Rosenfield RL, Barnes RB et al. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 1992; 327: 157-162
• 7 Tang T, Lord JM, Norman RJ et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility [CD-ROM]. Cochrane Database Syst Rev 2009;
• 8 Chang CT, Chen YC, Fang JT et al. Metformin-associated lactic acidosis: case reports and literature review. J Nephrol 2002; 15: 398-402
• 9 Geisthövel F, Frorath B, Brabant G. Acarbose reduces elevated testosterone serum concentrations in hyperinsulinaemic premenopausal women: a pilot study. Hum Reprod 1996; 11: 2377-2381
• 10 Laube H. Acarbose: an update therapeutic use in diabetes treatment. Clin Drug Invest 2000; 22: 141-156
• 11 Salvatore T, Giugliano D. Pharmacokinetic-pharmacodynamic relationships of acarbose. Clin Pharmacokinet 1996; 30: 94-106
• 12 Scheen AJ. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials. Diabetes Metab 1998; 24: 311-320
• 13 Ciotta L, Calogero AE, Farina M et al. Clinical, endocrine and metabolic effects of acarbose, an α-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance. Hum Reprod 2001; 16: 2066-2072
• 14 Penna IA, Canella PR, Reis RM et al. Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study. Hum Reprod 2005; 20: 2396-2401
• 15 Penna IA, Canella PR, Reis RM et al. Cardiovascular risk factors are reduced with a low dose of acarbose in obese patients with polycystic ovary syndrome. Fertil Steril 2007; 88: 519-522
• 16 Tuğrul S, Kutlu T, Pekin O et al. Clinical, endocrine, and metabolic effects of acarbose, a α-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome. Fertil Steril 2008; 90: 1144-1148
• 17 Hanjalic-Beck A, Gabriel B, Schaefer W et al. Metformin versus acarbose therapy in patients with polycystic ovary syndrome (PCOS): a prospective randomised double-blind study. Gynecol Endocrinol 2010; 26: 690-697
• 18 Sönmez AS, Yasar L, Savan K et al. Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome. Hum Reprod 2005; 20: 175-179
• 19 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25
• 20 Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A. (ed.) Polycystic ovary syndrome. Boston: Blackwell Scientific; 1992: 377-384
• 21 Kircher C, Smith KP. Acarbose for polycystic ovary syndrome. Ann Pharmacother 2008; 42: 847-851
• 22 Tauchert S, Schröder AK, Ortmann O et al. The use of oral antidiabetic drugs in the treatment of polycystic ovary syndrome. Zentralbl Gynakol 2003; 125: 507-514